| The evolution of drug resistance in clinical isolates of Candida albicans CB Ford, JM Funt, D Abbey, L Issi, C Guiducci, DA Martinez, T Delorey, ... elife 4, e00662, 2015 | 321 | 2015 |
| YMAP: a pipeline for visualization of copy number variation and loss of heterozygosity in eukaryotic pathogens DA Abbey, J Funt, MN Lurie-Weinberger, DA Thompson, A Regev, ... Genome Medicine 6, 1-16, 2014 | 118 | 2014 |
| Determinants of divergent adaptation and Dobzhansky-Muller interaction in experimental yeast populations JB Anderson, J Funt, DA Thompson, S Prabhu, A Socha, C Sirjusingh, ... Current Biology 20 (15), 1383-1388, 2010 | 101 | 2010 |
| Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19) J Kim, J Zhang, Y Cha, S Kolitz, J Funt, R Escalante Chong, S Barrett, ... Journal of translational medicine 18, 1-9, 2020 | 92 | 2020 |
| Comparing the biological impact of glatiramer acetate with the biological impact of a generic F Towfic, JM Funt, KD Fowler, S Bakshi, E Blaugrund, MN Artyomov, ... PloS one 9 (1), e83757, 2014 | 48 | 2014 |
| Leveraging existing data sets to generate new insights into Alzheimer’s disease biology in specific patient subsets KD Fowler, JM Funt, MN Artyomov, B Zeskind, SE Kolitz, F Towfic Scientific reports 5 (1), 14324, 2015 | 31 | 2015 |
| Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids S Kolitz, T Hasson, F Towfic, JM Funt, S Bakshi, KD Fowler, D Laifenfeld, ... Scientific reports 5 (1), 10191, 2015 | 21 | 2015 |
| Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone S Melamed-Gal, P Loupe, B Timan, V Weinstein, S Kolitz, J Zhang, J Funt, ... Eneurologicalsci 12, 19-30, 2018 | 18 | 2018 |
| Characterizing a glatiramer acetate related drug product R Schwartz, S Bakshi, KD Fowler, FG Towfic, JM Funt, BJ Zeskind, ... US Patent App. 14/147,167, 2014 | 17 | 2014 |
| Calculation of the entropy of lattice polymer models from Monte Carlo trajectories RP White, J Funt, H Meirovitch Chemical physics letters 410 (4-6), 430-435, 2005 | 12 | 2005 |
| Systems, methods, and environment for automated review of genomic data to identify downregulated and/or upregulated gene expression indicative of a disease or condition B Zeskind, KD Fowler, JM Funt, F Towfic, SE Kolitz US Patent App. 14/904,279, 2016 | 8 | 2016 |
| Integrity, standards, and QC-related issues with big data in pre-clinical drug discovery JF Brothers II, M Ung, R Escalante-Chong, J Ross, J Zhang, Y Cha, ... Biochemical Pharmacology 152, 84-93, 2018 | 5 | 2018 |
| Translational modeling for patients with RAS mutant tumors: Profiling the dual-MEK inhibitor IMM-1-104 in a humanized 3D assay. B Hall, P Nair, K Fowler, A Axel, S Kolitz, J Funt, S Barrett, B Zeskind, ... Journal of Clinical Oncology 40 (16_suppl), e15084-e15084, 2022 | 2 | 2022 |
| Metastasis: Leveraging transcriptomics to identify potential therapeutics M Ung, JM Funt, AC Lysaght, J Zhang, R Escalante-Chong, G Koytiger, ... Cancer Research 78 (13_Supplement), 5177-5177, 2018 | 2 | 2018 |
| Cachexia: Leveraging transcriptomics to identify potential therapeutics M Ung, KD Fowler, JM Funt, R Escalante-Chong, G Koytiger, S Kolitz, ... Cancer Research 78 (13_Supplement), 1509-1509, 2018 | 2 | 2018 |
| Gene expression studies comparing glatiramer acetate and proposed generics (P1. 212) B Zeskind, F Towfic, J Funt, K Fowler, S Bakshi, E Blaugrund, S Kolitz, ... Neurology 82 (10_supplement), P1. 212, 2014 | 2 | 2014 |
| Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the dual MEK inhibitor, IMM-6-415, enhances PD1 and CTLA4 checkpoint blockade in RAS mutant tumors B Hall, A Travesa, A Yamamura, A Axel, S Kolitz, J Funt, KD Fowler, ... J. Immunother. Cancer 10, A469, 2022 | 1 | 2022 |
| Genomic profiling and in vivo rat toxicity characterization of Copaxone and the Synthon European follow-on glatiramer acetate product S Kolitz, N Ashkenazi, B Timan, J Zhang, J Funt, O Beriozkin, A Konya, ... MULTIPLE SCLEROSIS JOURNAL 24, 940-941, 2018 | 1 | 2018 |
| 1524P Preliminary phase I safety and activity of IMM-1-104, an orally dosed universal RAS inhibitor that drives deep cyclic inhibition of the MAPK pathway at MEK, in patients … V Chung, AI Spira, AC Pavlick, D Sommerhalder, B Ma, V Hayreh, ... Annals of Oncology 35, S930-S931, 2024 | | 2024 |
| Activity of IMM-1-104 alone or in combination with chemotherapy in RAS-altered pancreatic cancer models P King, J Funt, S Kolitz, P Nair, J de Jong, A Yamamura, M Johnson, ... Cancer Research 84 (6_Supplement), 4195-4195, 2024 | | 2024 |
